Gilead Sciences (GILD) Presents New Data From the Company’s HIV Clinical Development Program and Latest Findings on the Impact of HIV PrEP at IDWeek

October 4, 2019 8:39 AM
Gilead Sciences, Inc. (NASDAQ: GILD) today announced important findings from the DISCOVER trial evaluating Descovy® (emtricitabine 200 mg and tenofovir ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles